Literature DB >> 8044823

Characterization and purification of a mycoplasma membrane-derived macrophage-activating factor.

S Caplan1, R Gallily, Y Barenholz.   

Abstract

A highly hydrophobic component derived from the membrane of Mycoplasma capricolum has been characterized, purified and assessed for its ability to activate macrophages to tumor cytotoxicity. Initially, crude membranes were evaluated for their solubility in a wide range of solvents. Despite differential solubility in the various solvents, the mycoplasma membranes retained their ability to potentiate macrophage tumor cytotoxicity. Mycoplasma membranes were further characterized by appraising their macrophage-activating ability subsequent to various chemical treatments: cleavage of ester and thioester bonds, oxidation of vicinal hydroxyl groups, and exposure to a broad range of pH. Only strong alkaline treatment (pH > 12) caused a reduction in mycoplasma membrane activity; all other chemical treatments were inconsequential. With potential therapeutic applications in mind, mycoplasma membranes were subjected to various physical treatments including heating, freezing/thawing, sonication, lyophilization and storage. The ability of the membranes to induce macrophage activation was stably maintained following all these treatments. Purification of membranes was initiated by a chloroform/methanol lipid extraction. Macrophage-activating ability was found predominantly in the interphase. Proteolytic cleavage with trypsin increased specific activity at least sixfold. Trypsinized fractions were solubilized in 2-chloroethanol and gel filtration was performed on a hydroxylated Sephadex LH-60 column. The active fraction from this column had a further tenfold increase in specific activity. Subsequent rounds of reverse-phase HPLC on this fraction yielded three to four peaks absorbing at 280 nm, of which only one had macrophage-activating ability.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8044823     DOI: 10.1007/bf01517177

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

1.  Action of proteolytic enzymes on purified bovine submaxillary mucin.

Authors:  Y HASHIMOTO; S TSUIKI; K NISIZAWA; W PIGMAN
Journal:  Ann N Y Acad Sci       Date:  1963-03-30       Impact factor: 5.691

2.  Optimization of the liposomes encapsulating a new lipopeptide CGP 31362 for efficient activation of tumoricidal properties in monocytes and macrophages.

Authors:  A Nii; T Utsugi; D Fan; Y Denkins; C Pak; D Brown; P van Hoogevest; I J Fidler
Journal:  J Immunother (1991)       Date:  1991-08

Review 3.  Antigenic character of membrane lipoglycans from Mollicutes--a review.

Authors:  P F Smith
Journal:  Isr J Med Sci       Date:  1987-05

4.  Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.

Authors:  J L Murray; E S Kleinerman; J E Cunningham; J R Tatom; K Andrejcio; J Lepe-Zuniga; L M Lamki; M G Rosenblum; H Frost; J U Gutterman
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

5.  Induction of macrophage-mediated cytolysis of neoplastic cells by mycoplasmas.

Authors:  J Loewenstein; S Rottem; R Gallily
Journal:  Cell Immunol       Date:  1983-04-15       Impact factor: 4.868

6.  Macrophage-activating factor extracted from mycoplasmas.

Authors:  M Takema; S Oka; K Uno; S Nakamura; H Arita; K Tawara; K Inaba; S Muramatsu
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Tumor necrosis factor as a mediator of Mycoplasma orale-induced tumor cell lysis by macrophages.

Authors:  R Gallily; T Sher; P Ben-Av; J Loewenstein
Journal:  Cell Immunol       Date:  1989-06       Impact factor: 4.868

8.  Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages.

Authors:  I J Fidler; A Raz; W E Fogler; R Kirsh; P Bugelski; G Poste
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

9.  Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.

Authors:  I J Fidler; W E Fogler; A F Brownbill; G Schumann
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

10.  Zymosan-stimulated tumor necrosis factor-alpha production by human monocytes. Down-modulation by phorbol ester.

Authors:  M V Sanguedolce; C Capo; P Bongrand; J L Mege
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

View more
  3 in total

1.  Mycoplasma orale infection affects K+ and Cl- currents in the HSG salivary gland cell line.

Authors:  K T Izutsu; S Fatherazi; C M Belton; D Oda; F D Cartwright; G E Kenny
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-06       Impact factor: 2.416

Review 2.  Molecular biology and pathogenicity of mycoplasmas.

Authors:  S Razin; D Yogev; Y Naot
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

3.  Indomethacin sensitizes resistant transformed cells to macrophage cytotoxicity.

Authors:  Hana Totary-Jain; Ronit Vogt Sionov; Ruth Gallily
Journal:  Immunol Lett       Date:  2016-05-17       Impact factor: 3.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.